Company news
Ocumension Therapeutics (HKEX:1477) news
Ocumension Therapeutics news releases on 6ix. Latest, Aug 12, 2024: OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake…
Press releases & updates
OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship
August 12, 2024
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
March 21, 2024
Ocumension Therapeutics Announces 2023 Interim Results
August 24, 2023
Ocumension Therapeutics Announces 2022 Annual Results
March 30, 2023
Ocumension Therapeutics : INSIDE INFORMATION NEW DRUG APPLICATION OF OUR CORE PRODUCT OT-401 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
June 21, 2022
Ocumension Therapeutics : Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength
August 25, 2021
Ocumension Therapeutics : Announces 2021 Interim Results
August 20, 2021
Ocumension Therapeutics : NOTICE OF EXTRAORDINARY GENERAL MEETING
August 10, 2021
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT IND APPLICATION RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101 IN CHINA
May 12, 2021
Ocumension Therapeutics : COMPLETION OF THE TRANSACTIONS UNDER SHARE PURCHASE AGREEMENT
April 23, 2021
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT APPROVAL FOR COMMENCEMENT OF INITIAL PEDIATRIC STUDY PLAN FOR OT-101 IN THE UNITED STATES
April 22, 2021
Ocumension Therapeutics : (I) DISCLOSEABLE TRANSACTIONS RELATING TO THE EXCLUSIVE LICENSE AGREEMENT AND THE SHARE PURCHASE AGREEMENT AND (II) THE WARRANT SUBSCRIPTION AGREEMENT WITH ALIMERA SCIENCES, INC.
April 14, 2021
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE III CLINICAL TRIAL OF OT-101 IN THE UNITED STATES AND THE PLANNED REAL WORLD STUDY FOR OT-101 IN CHINA
April 7, 2021
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR OT-401 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
April 7, 2021
Ocumension Therapeutics : CHANGE OF NON-EXECUTIVE DIRECTOR
March 19, 2021
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHENZHEN-HONG KONG STOCK CONNECT
March 15, 2021
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT SECOND PHASE III CLINICAL TRIAL OF OT-301 APPROVED IN CHINA
March 3, 2021
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT SELECTION OF THE SHARES OF THE COMPANY AS A CONSTITUENT OF CERTAIN INDEXES OF HANG SENG INDEXES COMPANY LIMITED
March 1, 2021
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF OT-1001 (ZERVIATE) APPROVED IN CHINA
September 21, 2020
Ocumension Therapeutics : ANNOUNCEMENT ACQUISITION OF 100% EQUITY INTEREST IN SUZHOU XIAXIANG AND CHANGE IN USE OF PROCEEDS FROM THE LISTING
September 11, 2020
Ocumension Therapeutics : INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2020
August 26, 2020